Bringing Novel Gene Therapies to Patients with Rare Diseases

Dimension Therapeutics is a gene therapy company developing novel treatments for rare diseases

Dimension is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with lead programs in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics across a wide array of single-gene rare diseases.

Read More

APRIL 23, 2015
Dimension Therapeutics to Develop Gene Therapy Treatments for Patients with Ornithine Transcarbamylase (OTC) Deficiency and Glycogen Storage Disease Type Ia (GSDIa)

Read More

APRIL 21, 2015
Dimension Therapeutics Secures $65 Million in Oversubscribed Series B Financing

Read More

JANUARY 28, 2015
Dimension Therapeutics Appoints Successful Biopharma Leader Mary Thistle as Chief Business Officer

Read More

DECEMBER 2, 2014
Dimension Therapeutics Expands Leadership Team, Names Eric Crombez M.D., as Chief Medical Officer

Read More

SEPTEMBER 22, 2014
FierceBiotech names Dimension Therapeutics as one of its "Fierce 15" Biotech Companies of 2014

Read More

SEPTEMBER 16, 2014
Dimension Therapeutics Names Annalisa Jenkins as Chief Executive Officer

Read More